Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

$BTX
Get the next $BTX alert in real time by email

Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, today announced the appointment of Michael Andreeff, M.D., Ph.D. to Brooklyn's Scientific Advisory Board, effective May 21, 2021.

Dr. Andreeff currently serves as a Professor of Medicine at MD Anderson Cancer Center where he holds the Paul and Mary Haas Chair in Genetics and is the Chief of Molecular Hematology and Therapy. Dr. Andreeff received his M.D. and Ph.D. from the University of Heidelberg, Germany, and additional training at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Andreff has been a pioneer in flow cytometry since 1971, when he established the first flow cytometry laboratory at the University of Heidelberg and organized the first European flow cytometry conference. In 1977 he joined MSKCC, became head of the Leukemia Cell Biology and Hematopathology flow cytometry laboratory, and organized the first Clinical Cytometry Conference in 1986. Since 1990 he has been Professor of Medicine at MD Anderson Cancer Center. He has published over 700 peer-reviewed papers, 5 books and 75 book chapters.

"Dr. Andreeff brings a tremendous amount of experience in developing treatments for leukemia and I am thrilled to welcome him to Brooklyn's Scientific Advisory Board," said Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President of Brooklyn. "He is an established leader in analyzing the interactions between leukemia stem cells and their microenvironment. He has also laid the foundation for using mesenchymal stem cells in cancer therapy. Dr. Andreeff's expertise will be crucial as we continue to advance our work in the gene editing and cell therapy space."

"Having worked extensively in the leukemia space, I am eager to join the Brooklyn team and contribute to their efforts to develop impactful oncology therapies," said Dr. Andreeff. "With the recent license with Factor Bioscience Limited and Novellus Therapeutics Limited's gene editing technology, Brooklyn has tremendous potential as a leader in cancer therapy with a diverse pipeline of products. I am excited to be a part of this team."

About Brooklyn ImmunoTherapeutics

Brooklyn is exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using leading edge gene editing/cell therapy technology through the newly acquired license from Factor Bioscience and Novellus Therapeutics.

Brooklyn's most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.

Get the next $BTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BTX

DatePrice TargetRatingAnalyst
12/29/2021$9.00Overweight
Cantor Fitzgerald
10/6/2021$20.00Buy
Maxim Group
More analyst ratings

$BTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

    Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution   Declaration- 4/1/2025 Ex-Date- 4/15/2025 Record- 4/15/2025 Payable- 5/1/2025   Ticker Distribution Change From Prior Distribution   BlackRock Municipal Income Quality Trust*  BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municip

    $BBN
    $BCAT
    $BCX
    $BDJ
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable
  • Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

    Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

    $BBN
    $BCAT
    $BCX
    $BDJ
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable
  • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

    Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution     Declaration- 3/3/2025 Ex-Date- 3/14/2025 Record- 3/14/2025 Payable- 4/1/2025     Ticker     Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock

    $BBN
    $BCAT
    $BCX
    $BDJ
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable

$BTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BTX
SEC Filings

See more

$BTX
Leadership Updates

Live Leadership Updates

See more
  • Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

    SAN DIEGO, May 31, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn" or the "Company"), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc., as Interim Chief Executive Officer and President. He will replace Howard J. Federoff, M.D., Ph.D., Chief Executive Officer and President, who departs to focus on building a new venture. The Company also announces the appointment of Andrew Jackson as Chief

  • Amarin Announces Appointment of New Directors and Board Leadership Changes

    Erin Enright and Alfonso "Chito" Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company's Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Actions Reflect Company and Board's Commitment to Ongoing Refreshment and Enhancement DUBLIN, Ireland and BRIDGEWATER, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso "Chito" Zulueta to the Board, effective immediately. Ms. Enright and Mr. Zulueta will sta

    $AMRN
    $BTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

    NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces the appointment of two new members of the Company's Board of Directors. Erin S. Enright has served on multiple Boards of Directors, including within the medical and life sciences arenas, such as Keystone Dental (serving as Audit Committee Chair), Medical Facilities Corporation (serving as Audit and Investment Committee Chair), and Dynatronics Corporation (serving on the Audit, Compensati

$BTX
Financials

Live finance-specific insights

See more
  • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

    Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution   Declaration- 4/1/2025 Ex-Date- 4/15/2025 Record- 4/15/2025 Payable- 5/1/2025   Ticker Distribution Change From Prior Distribution   BlackRock Municipal Income Quality Trust*  BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock Investment Quality Municipal Trust, Inc.* BKN $0.057000 - BlackRock Municip

    $BBN
    $BCAT
    $BCX
    $BDJ
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable
  • Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions

    Today, BlackRock Resources & Commodities Strategy Trust (NYSE:BCX), BlackRock Enhanced Equity Dividend Trust (NYSE:BDJ), BlackRock Energy and Resources Trust (NYSE:BGR), BlackRock Enhanced International Dividend Trust (NYSE:BGY), BlackRock Health Sciences Trust (NYSE:BME), BlackRock Health Sciences Term Trust (NYSE:BMEZ), BlackRock Enhanced Global Dividend Trust (NYSE:BOE), BlackRock Utilities, Infrastructure & Power Opportunities Trust (NYSE:BUI), BlackRock Enhanced Large Cap Core Fund, Inc. (NYSE:CII), BlackRock Science and Technology Trust (NYSE:BST), BlackRock Science and Technology Term Trust (NYSE:BSTZ), BlackRock Technology and Private Equity Term Trust (NYSE:BTX), BlackRock Capital

    $BBN
    $BCAT
    $BCX
    $BDJ
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable
  • Distribution Dates and Amounts Announced for Certain BlackRock Closed-End Funds

    Certain BlackRock closed-end funds (the "Funds") announced distributions today as detailed below. Municipal Funds: National Funds Ticker Distribution     Declaration- 3/3/2025 Ex-Date- 3/14/2025 Record- 3/14/2025 Payable- 4/1/2025     Ticker     Distribution Change From Prior Distribution BlackRock Municipal Income Quality Trust* BYM $0.055500 - BlackRock Long-Term Municipal Advantage Trust* BTA $0.049500 - BlackRock MuniAssets Fund, Inc.* MUA $0.055500 - BlackRock Municipal Income Trust* BFK $0.050000 - BlackRock

    $BBN
    $BCAT
    $BCX
    $BDJ
    Finance Companies
    Finance
    Finance/Investors Services
    Trusts Except Educational Religious and Charitable

$BTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more